Related references
Note: Only part of the references are listed.The Nucleocapsid Protein of Rift Valley Fever Virus Is a Potent Human CD8+ T Cell Antigen and Elicits Memory Responses
Weidong Xu et al.
PLOS ONE (2013)
Breaking the chain: Rift Valley fever virus control via livestock vaccination
Brian H. Bird et al.
CURRENT OPINION IN VIROLOGY (2012)
Direct Effects of Type I Interferons on Cells of the Immune System
Sandra Hervas-Stubbs et al.
CLINICAL CANCER RESEARCH (2011)
Potent CD8(+) T-Cell Immunogenicity in Humans of a Novel Heterosubtypic Influenza A Vaccine, MVA-NP+M1
Tamara K. Berthoud et al.
CLINICAL INFECTIOUS DISEASES (2011)
MVA and NYVAC as Vaccines against Emergent Infectious Diseases and Cancer
Carmen E. Gomez et al.
CURRENT GENE THERAPY (2011)
Contributions of Antinucleoprotein IgG to Heterosubtypic Immunity against Influenza Virus
Mark W. LaMere et al.
JOURNAL OF IMMUNOLOGY (2011)
Phase 1 Safety and Immunogenicity Testing of DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-like Particles
Paul A. Goepfert et al.
JOURNAL OF INFECTIOUS DISEASES (2011)
Rift Valley Fever: Recent Insights into Pathogenesis and Prevention
Hani Boshra et al.
JOURNAL OF VIROLOGY (2011)
DNA priming and influenza vaccine immunogenicity: two phase 1 open label randomised clinical trials
Julie E. Ledgerwood et al.
LANCET INFECTIOUS DISEASES (2011)
Anti-Nucleocapsid Protein Immune Responses Counteract Pathogenic Effects of Rift Valley Fever Virus Infection in Mice
Petrus Jansen van Vuren et al.
PLOS ONE (2011)
Recombinant Rift Valley fever vaccines induce protective levels of antibody in baboons and resistance to lethal challenge in mice
James F. Papin et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2011)
Safety and immunogenicity of a modified pox vector-based HIV/AIDS vaccine candidate expressing Env, Gag, Pot and Nef proteins of HIV-1 subtype B (MVA-B) in healthy HIV-1-uninfected volunteers: A phase I clinical trial (RISVAC02)
Felipe Garcia et al.
VACCINE (2011)
A DNA vaccine encoding ubiquitinated Rift Valley fever virus nucleoprotein provides consistent immunity and protects IFNAR-/- mice upon lethal virus challenge
Hani Boshra et al.
VACCINE (2011)
A Temporal Role Of Type I Interferon Signaling in CD8+ T Cell Maturation during Acute West Nile Virus Infection
Amelia K. Pinto et al.
PLOS PATHOGENS (2011)
Rift Valley Fever in Ruminants, Republic of Comoros, 2009
Matthieu Roger et al.
EMERGING INFECTIOUS DISEASES (2011)
Rift Valley Fever Outbreak in Livestock in Kenya, 2006-2007
Peninah Munyua et al.
AMERICAN JOURNAL OF TROPICAL MEDICINE AND HYGIENE (2010)
Vaccination of Metastatic Renal Cancer Patients with MVA-5T4: A Randomized, Double-Blind, Placebo-Controlled Phase III Study
Robert J. Amato et al.
CLINICAL CANCER RESEARCH (2010)
Development and characterization of monoclonal antibodies against Rift Valley fever virus nucleocapsid protein generated by DNA immunization
Raquel Martin-Folgar et al.
MABS (2010)
Priming Immunization with DNA Augments Immunogenicity of Recombinant Adenoviral Vectors for Both HIV-1 Specific Antibody and T-Cell Responses
Richard A. Koup et al.
PLOS ONE (2010)
Phase I Safety and Immunogenicity Evaluation of MVA-CMDR, a Multigenic, Recombinant Modified Vaccinia Ankara-HIV-1 Vaccine Candidate
Jeffrey R. Currier et al.
PLOS ONE (2010)
Evaluation of the efficacy and safety of the Rift Valley Fever Clone 13 vaccine in sheep
Baptiste Dungu et al.
VACCINE (2010)
Protection against lethal Rift Valley fever virus (RVFV) infection in transgenic IFNAR-/- mice induced by different DNA vaccination regimens
Gema Lorenzo et al.
VACCINE (2010)
Rift Valley fever virus (Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology, vectors, diagnostics and prevention
Michel Pepin et al.
VETERINARY RESEARCH (2010)
Vaccination with DNA Plasmids Expressing Gn Coupled to C3d or Alphavirus Replicons Expressing Gn Protects Mice against Rift Valley Fever Virus
Nitin Bhardwaj et al.
PLOS NEGLECTED TROPICAL DISEASES (2010)
Rift Valley Fever during Rainy Seasons, Madagascar, 2008 and 2009
Soa Fy Andriamandimby et al.
EMERGING INFECTIOUS DISEASES (2010)
Vaccinia virus vaccines: Past, present and future
Bertram L. Jacobs et al.
ANTIVIRAL RESEARCH (2009)
Phase II trial of Modified Vaccinia Ankara (MVA) virus expressing 5T4 and high dose Interleukin-2 (IL-2) in patients with metastatic renal cell carcinoma
Howard L. Kaufman et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2009)
Vaccinia Virus-Mediated Inhibition of Type I Interferon Responses Is a Multifactorial Process Involving the Soluble Type I Interferon Receptor B18 and Intracellular Components
Zoe Waibler et al.
JOURNAL OF VIROLOGY (2009)
Characterisation of immune responses and protective efficacy in mice after immunisation with Rift Valley Fever virus cDNA constructs
Nina Lagerqvist et al.
VIROLOGY JOURNAL (2009)
Rift Valley Fever, Mayotte, 2007-2008
Daouda Sissoko et al.
EMERGING INFECTIOUS DISEASES (2009)
The poxvirus vectors MVA and NYVAC as gene delivery systems for vaccination against infectious diseases and cancer
Carmen E. Gomez et al.
CURRENT GENE THERAPY (2008)
Priming with DNA plasmids encoding the nucleocapsid protein and glycoprotein precursors from Rift Valley fever virus accelerates the immune responses induced by an attenuated vaccine in sheep
Gerna Lorenzo et al.
VACCINE (2008)
Modified vaccinia virus Ankara induces toll-like receptor-independent type I interferon responses
Zoe Waibler et al.
JOURNAL OF VIROLOGY (2007)
Protective immune responses induced by different recombinant vaccine regimes to Rift Valley fever
D. B. Wallace et al.
VACCINE (2006)
Immunogenicity of combination DNA vaccines for Rift Valley fever virus, tick-borne encephalitis virus, Hantaan virus, and Crimean Congo hemorrhagic fever virus
Kristin Spik et al.
VACCINE (2006)
Direct stimulation of T cells by type IIFN enhances the CD8+ T cell response during cross-priming
Agnes Le Bon et al.
JOURNAL OF IMMUNOLOGY (2006)
A clinical trial of prime-boost immunisation with the candidate malaria vaccines RTS,S/AS02A and MVA-CS
SJ Dunachie et al.
VACCINE (2006)
Type IIFN negatively regulates CD8(+) T cell responses through IL-10-Producing CD4(+) T regulatory 1 cells
N Dikopoulos et al.
JOURNAL OF IMMUNOLOGY (2005)
Type I interferon as a link between innate and adaptive immunity through dendritic cell stimulation
DF Tough
LEUKEMIA & LYMPHOMA (2004)
A prime-boost immunisation regimen using DNA followed by recombinant modified vaccinia virus Ankara induces strong cellular immune responses against the Plasmodium falciparum TRAP antigen in chimpanzees
J Schneider et al.
VACCINE (2001)
Enhanced immunogenicity of CD4+ T-cell responses and protective efficacy of a DNA-modified vaccinia virus Ankara prime-boost vaccination regimen for murine tuberculosis
H McShane et al.
INFECTION AND IMMUNITY (2001)
Vaccinia expression of Mycobacterium tuberculosis-secreted proteins:: tissue plasminogen activator signal sequence enhances expression and immunogenicity of M-tuberculosis Ag85
AS Malin et al.
MICROBES AND INFECTION (2000)
Share Paper
